METALYSE Infusion
Tenecteplase
"10,000 U (50mg)"
Boehringer Ingelheim GmbH
| Pack size | 1 Vial (Dry) + 1 Solvent Syringe (10ml) |
|---|---|
| Dispensing mode | POM |
| Source | GERMANY |
| Agent | GULF DRUG EST. |
| Retail Price | 5503.50 AED |
Available as:
Indications
METALYSE Infusion is used for:
Acute myocardial infarction
Adult Dose
Intravenous
Acute myocardial infarction
Adult: 30-50 mg as a single bolus dose over 5-10 sec as soon as possible after the onset of symptoms. The dose is based on body weight. Max: 50mg.
Administer ASAP (within 30 minutes) after onset of acute MI
30-50 mg IV bolus over 5 sec once (based on weight)
<60 kg: 30 mg
60-70 kg: 35 mg
70-80 kg: 40 mg
80-90 kg: 45 mg
>90 kg: 50 mg
Child Dose
Renal Dose
Administration
IV Preparation
Add 10 mL SWI to a 50 mg vial using TwinPak® device directing stream of diluent into powder. If foaming (usually slight) occurs, leave vial undisturbed for several minutes to allow dissipation of any large bubbles. Gently swirl (do not shake) until contents are completely dissolved.
Contra Indications
Patients at risk of cerebral bleeding including severe hypertension, history of stroke, intracranial or intraspinal surgery or trauma within 2 mth, arteriovenous malformation or aneurysm, cerebral neoplasm. Haemorrhage or known bleeding diathesis.
Precautions
Patients with increased risk of bleeding. Recent history of GI or genitourinary bleed, recent major surgery, previous puncture of noncompressible vessels, hypertension (>180/110 mm Hg), high risk of left heart thrombus, acute pericarditis, subacute bacterial endocarditis, coagulation defects, invasive procedures, haemorrhagic ophthalmic conditions. Elderly, pregnancy and lactation. Severe hepatic impairment.
Lactation: not known whether drug crosses into breast milk, nursing not a priority in AMI
Pregnancy-Lactation
Pregnancy
Drug has been shown to elicit maternal and embryo toxicity in rabbits given multiple IV administrations; subsequent embryonic deaths were secondary to maternal hemorrhage and no fetal anomalies were observed
Lactation
Not known whether drug crosses into breast milk, nursing not a priority in AMI
Interactions
Increased risk of haemorrhage with heparin, oral anticoagulants, antiplatelet drugs and other drugs that can affect platelet function.
Adverse Effects
Side effects of Tenecteplase :
>10%
Minor bleeding (22%)
Frequency Not Defined
Reperfusion arrhythmias
MI
Fever
Nausea
Vomiting
Cholesterol embolization
Allergic reaction
Mechanism of Action
Tenecteplase is a biosynthetic form of the enzyme human tissue-type plasminogen activator (t-PA). It is a fibrin-specific thrombolytic, converts plasminogen to plasmin, a proteolytic enzyme that has fibrinolytic effects.
Note
METALYSE "10,000 U (50mg)" Infusion manufactured by Boehringer Ingelheim GmbH. Its generic name is Tenecteplase. METALYSE is availble in United Arab Emirates.
Farmaco UAE drug index information on METALYSE Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.